Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by L JEFFREY MEDEIROS and KEN HE YOUNG.
L JEFFREY MEDEIROS
Connection Strength
5.180
KEN HE YOUNG
  1. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019 10; 16(10):634-652.
    View in: PubMed
    Score: 0.175
  2. Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Front Oncol. 2019; 9:107.
    View in: PubMed
    Score: 0.168
  3. Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol. 2018; 8:351.
    View in: PubMed
    Score: 0.163
  4. Diffuse large B-cell lymphoma. Pathology. 2018 Jan; 50(1):74-87.
    View in: PubMed
    Score: 0.154
  5. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev. 2018 01; 32(1):8-28.
    View in: PubMed
    Score: 0.151
  6. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017 03 23; 129(12):1658-1668.
    View in: PubMed
    Score: 0.145
  7. Distinguishing Between Hepatosplenic T-cell Lymphoma and ?d T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis. Am J Surg Pathol. 2017 01; 41(1):82-93.
    View in: PubMed
    Score: 0.145
  8. NF-?B signaling pathway and its potential as a target for therapy in lymphoid neoplasms. Blood Rev. 2017 03; 31(2):77-92.
    View in: PubMed
    Score: 0.142
  9. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol. 2016 10; 29(10):1118-42.
    View in: PubMed
    Score: 0.140
  10. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88.
    View in: PubMed
    Score: 0.138
  11. Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk Lymphoma. 2016 12; 57(12):2804-2812.
    View in: PubMed
    Score: 0.138
  12. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016 May; 57(5):1104-13.
    View in: PubMed
    Score: 0.135
  13. Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev. 2016 05; 30(3):189-200.
    View in: PubMed
    Score: 0.134
  14. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91.
    View in: PubMed
    Score: 0.132
  15. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. Am J Surg Pathol. 2015 Aug; 39(8):1132-9.
    View in: PubMed
    Score: 0.131
  16. Waldenstr?m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015 Jun 24; 8:74.
    View in: PubMed
    Score: 0.130
  17. Peripheral T-cell lymphoma with unusual clinical presentation of rhabdomyolysis. Hematol Oncol. 2017 Mar; 35(1):125-129.
    View in: PubMed
    Score: 0.129
  18. Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. Ann Diagn Pathol. 2014 Aug; 18(4):203-9.
    View in: PubMed
    Score: 0.120
  19. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20.
    View in: PubMed
    Score: 0.117
  20. Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications. Hum Pathol. 2013 Dec; 44(12):2658-67.
    View in: PubMed
    Score: 0.115
  21. MYC/BCL2 double-hit high-grade B-cell lymphoma. Adv Anat Pathol. 2013 Sep; 20(5):315-26.
    View in: PubMed
    Score: 0.115
  22. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013 Jul 18; 122(3):328-40.
    View in: PubMed
    Score: 0.112
  23. Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas. Hum Pathol. 2012 Nov; 43(11):1789-98.
    View in: PubMed
    Score: 0.107
  24. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol. 2013 Jan; 44(1):110-21.
    View in: PubMed
    Score: 0.107
  25. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012 Apr 19; 119(16):3668-83.
    View in: PubMed
    Score: 0.103
  26. Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. Hum Pathol. 2012 Apr; 43(4):467-80.
    View in: PubMed
    Score: 0.102
  27. EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. Histopathology. 2022 Feb; 80(3):575-588.
    View in: PubMed
    Score: 0.051
  28. Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. Ann Diagn Pathol. 2020 Dec; 49:151636.
    View in: PubMed
    Score: 0.047
  29. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Mod Pathol. 2020 03; 33(3):367-379.
    View in: PubMed
    Score: 0.043
  30. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 04; 7(4):644-657.
    View in: PubMed
    Score: 0.042
  31. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol. 2019 06; 32(6):741-754.
    View in: PubMed
    Score: 0.042
  32. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018 10 25; 132(17):1805-1817.
    View in: PubMed
    Score: 0.041
  33. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia. 2018 06; 20(6):574-593.
    View in: PubMed
    Score: 0.040
  34. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980.
    View in: PubMed
    Score: 0.040
  35. Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2018 05 15; 24(10):2304-2311.
    View in: PubMed
    Score: 0.039
  36. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol. 2018 02; 31(2):327-336.
    View in: PubMed
    Score: 0.038
  37. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. Am J Surg Pathol. 2017 Oct; 41(10):1309-1321.
    View in: PubMed
    Score: 0.038
  38. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget. 2018 Jan 02; 9(1):346-360.
    View in: PubMed
    Score: 0.038
  39. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017 Aug; 187(8):1700-1716.
    View in: PubMed
    Score: 0.037
  40. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844.
    View in: PubMed
    Score: 0.037
  41. Immunophenotypic Shifts in Primary Cutaneous ?d T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol. 2017 Apr; 41(4):431-445.
    View in: PubMed
    Score: 0.037
  42. Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (?d) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous ?d T-Cell Lymphomas. Am J Surg Pathol. 2017 Feb; 41(2):204-215.
    View in: PubMed
    Score: 0.036
  43. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 2016 Dec 06; 7(49):80599-80611.
    View in: PubMed
    Score: 0.036
  44. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. 2016 12 29; 128(26):3083-3100.
    View in: PubMed
    Score: 0.036
  45. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-a inhibitor therapy and literature review. Ann Diagn Pathol. 2017 Feb; 26:16-22.
    View in: PubMed
    Score: 0.036
  46. Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists. Mol Cytogenet. 2016; 9:62.
    View in: PubMed
    Score: 0.035
  47. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2016 07 15; 22(14):3593-605.
    View in: PubMed
    Score: 0.034
  48. Simultaneous deletion of 3'ETV6 and 5'EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Mol Cytogenet. 2016; 9:23.
    View in: PubMed
    Score: 0.034
  49. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY). 2016 Feb; 8(2):345-65.
    View in: PubMed
    Score: 0.034
  50. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):2401-16.
    View in: PubMed
    Score: 0.034
  51. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2016 Jan 10; 34(2):160-8.
    View in: PubMed
    Score: 0.034
  52. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56.
    View in: PubMed
    Score: 0.034
  53. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2015 Dec; 28(12):1555-73.
    View in: PubMed
    Score: 0.033
  54. Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of ?d T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With a? T-Cell Large Granular Lymphocytic Leukemia. [corrected]. Am J Clin Pathol. 2015 Oct; 144(4):607-19.
    View in: PubMed
    Score: 0.033
  55. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol. 2015 Oct; 28(10):1297-314.
    View in: PubMed
    Score: 0.033
  56. Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. 2015 Sep; 28(9):1202-13.
    View in: PubMed
    Score: 0.033
  57. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? Oncotarget. 2015 Jun 10; 6(16):13933-45.
    View in: PubMed
    Score: 0.032
  58. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45.
    View in: PubMed
    Score: 0.032
  59. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Mar 20; 6(8):5615-33.
    View in: PubMed
    Score: 0.032
  60. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol. 2015 Jun; 28(6):787-98.
    View in: PubMed
    Score: 0.032
  61. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54.
    View in: PubMed
    Score: 0.031
  62. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res. 2014 Oct 01; 20(19):5113-23.
    View in: PubMed
    Score: 0.031
  63. Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat. 2014 Aug; 147(1):1-14.
    View in: PubMed
    Score: 0.031
  64. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Jun 15; 120(12):1818-29.
    View in: PubMed
    Score: 0.030
  65. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014 May 01; 20(9):2338-49.
    View in: PubMed
    Score: 0.030
  66. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014 Jul; 27(7):958-71.
    View in: PubMed
    Score: 0.029
  67. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Oct 10; 122(15):2630-40.
    View in: PubMed
    Score: 0.029
  68. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014 Mar; 55(3):624-7.
    View in: PubMed
    Score: 0.029
  69. Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. Am J Surg Pathol. 2013 Aug; 37(8):1290-7.
    View in: PubMed
    Score: 0.029
  70. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 30; 121(22):4529-40.
    View in: PubMed
    Score: 0.028
  71. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 16; 121(20):4021-31; quiz 4250.
    View in: PubMed
    Score: 0.028
  72. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Apr 04; 121(14):2715-24.
    View in: PubMed
    Score: 0.028
  73. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012 Nov 08; 120(19):3986-96.
    View in: PubMed
    Score: 0.027
  74. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013 Feb; 98(2):255-63.
    View in: PubMed
    Score: 0.027
  75. High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology. 2012 Nov; 61(5):945-54.
    View in: PubMed
    Score: 0.027
  76. Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol. 2012 Jul; 36(7):1000-8.
    View in: PubMed
    Score: 0.026
  77. Advances in the molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol. 2012 Sep; 43(9):1347-62.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.